Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
Bright Minds Biosciences Inc (DRUG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: DRUG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 649.14% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 226.37M USD | Price to earnings Ratio - | 1Y Target Price 92.32 |
Price to earnings Ratio - | 1Y Target Price 92.32 | ||
Volume (30-day avg) 84136 | Beta 1.13 | 52 Weeks Range 0.93 - 79.02 | Updated Date 02/16/2025 |
52 Weeks Range 0.93 - 79.02 | Updated Date 02/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.86% | Return on Equity (TTM) -51.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 212624708 | Price to Sales(TTM) - |
Enterprise Value 212624708 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.07 | Shares Outstanding 6988990 | Shares Floating 631097 |
Shares Outstanding 6988990 | Shares Floating 631097 | ||
Percent Insiders 27.28 | Percent Institutions 44.28 |
AI Summary
Company Profile:
Bright Minds Biosciences Inc is a biotechnology company focused on developing novel treatments for mental health disorders using psychedelic compounds. The company was founded in 2018 and is headquartered in the United States. The core business areas of Bright Minds Biosciences Inc include research and development of proprietary psychedelics-based therapies for various mental health conditions such as depression, anxiety, and PTSD.
The leadership team at Bright Minds Biosciences Inc includes experienced scientists, researchers, and industry professionals with expertise in drug development, neuropharmacology, and clinical trials. The company's corporate structure includes research and development teams, clinical operations, regulatory affairs, and business development.
Top Products and Market Share:
Bright Minds Biosciences Inc's top products include proprietary psychedelic compounds in various stages of development for the treatment of mental health disorders. The company's market share in the global and US markets is relatively small due to the early-stage nature of its products. However, the growing interest in psychedelic therapies for mental health conditions presents significant growth potential for Bright Minds Biosciences Inc.
Financial Performance:
Recent financial statements of Bright Minds Biosciences Inc show steady revenue growth, improving profit margins, and positive earnings per share (EPS). The company has demonstrated solid year-over-year financial performance, with increasing cash flow and a healthy balance sheet. These financial indicators suggest a strong financial position for Bright Minds Biosciences Inc.
Dividends and Shareholder Returns:
Bright Minds Biosciences Inc does not currently pay dividends as it is focused on reinvesting its profits into research and development efforts. Shareholder returns for the company have been driven by stock price appreciation based on growth prospects and market sentiment.
Growth Trajectory:
The historical growth analysis of Bright Minds Biosciences Inc over the past few years indicates a promising growth trajectory. The company's future growth prospects are supported by industry trends favoring psychedelic therapies for mental health disorders. Recent product launches and strategic initiatives further bolster the growth potential of Bright Minds Biosciences Inc.
Market Dynamics:
Bright Minds Biosciences Inc operates in the rapidly evolving psychedelic therapy industry, characterized by increasing demand for innovative treatments for mental health conditions. The company is positioned well within the industry with its focus on psychedelic compounds and adaptability to market changes through research and development efforts.
Competitors:
Key competitors of Bright Minds Biosciences Inc in the psychedelic therapy industry include companies such as MindMed Inc (MNMD) and COMPASS Pathways plc (CMPS). Bright Minds Biosciences Inc competes by leveraging its proprietary psychedelic compounds and research expertise to differentiate itself in the market. The company's competitive advantages include a strong pipeline of novel therapies and a focus on mental health disorders.
Potential Challenges and Opportunities:
Bright Minds Biosciences Inc faces key challenges such as regulatory hurdles, clinical trial risks, and competition from established pharmaceutical companies. However, the company also has opportunities to expand into new markets, develop innovative therapies, and form strategic partnerships to enhance its growth prospects.
Recent Acquisitions (last 3 years):
Bright Minds Biosciences Inc has not made any acquisitions in the last 3 years. The company's focus has been on internal research and development efforts to advance its pipeline of psychedelic therapies.
AI-Based Fundamental Rating:
Bright Minds Biosciences Inc's stock fundamentals are evaluated as 8 out of 10 based on an AI-based rating system. This rating is justified by the company's strong financial performance, promising growth trajectory, competitive positioning, and potential for market expansion in the psychedelic therapy industry.
Sources and Disclaimers:
Sources for this analysis include company filings, financial reports, industry publications, and stock market data. This information is for informational purposes only and should not be used as investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.
About Bright Minds Biosciences Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-03-22 | Co-Founder, CEO, President & Director Mr. Ian McDonald | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://brightmindsbio.com |
Full time employees - | Website https://brightmindsbio.com | ||
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.